title: Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986-1996).
abstract: OBJECTIVE
  To evaluate time to first recurrence (TFR) and overall survival in cats with presumed vaccine-associated sarcomas (VAS) treated with excision.
  
  
  METHODS
  Retrospective study.
  
  
  METHODS
  61 cats with presumed VAS.
  
  
  METHODS
  Medical records of cats that received excision as the only initial treatment for presumed VAS were reviewed to evaluate prognosis. Overall survival curves and TFR were determined.
  
  
  RESULTS
  Median TFR was 94 days. Median TFR for tumors treated with excision performed at a referral institution (274 days) was significantly longer than that for tumors excised by a referring veterinarian (66 days). Radical first excision yielded significantly longer median TFR (325 days) than did marginal first excision (79 days). Cats with tumors located on the limbs had longer median TFR (325 days) than cats with tumors located in other sites (66 days). Median overall survival time was 576 days. Significant differences in survival times between groups were not detected. Few cats (13.8%) receiving only surgical treatment had long-term (> 2 years) survival.
  
  
  CONCLUSIONS
  Radical first excision of presumed VAS is essential for extended TFR. Current recommendations for vaccination of the distal portions of the extremities are appropriate, because this practice permits radical excision of tumors (amputation) that develop at vaccination sites; however, surgery alone is seldom curative.
authors.affiliation: Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison 53706, USA.
authors.forename: A E
authors.initials: AE
authors.lastname: Hershey
authors.forename: K U
authors.initials: KU
authors.lastname: Sorenmo
authors.forename: M J
authors.initials: MJ
authors.lastname: Hendrick
authors.forename: F S
authors.initials: FS
authors.lastname: Shofer
authors.forename: D M
authors.initials: DM
authors.lastname: Vail
mesh_terms: D000818:Animals; D002371:Cat Diseases / Q000209:etiology / Q000473:pathology / Q000601:surgery*; D002415:Cats; D005260:Female; D005354:Fibrosarcoma / Q000209:etiology / Q000601:surgery / Q000662:veterinary*; D008297:Male; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000662:veterinary*; D011379:Prognosis; D011819:Rabies Vaccines / Q000009:adverse effects*; D013902:Radiography, Thoracic / Q000662:veterinary; D012189:Retrospective Studies; D012983:Soft Tissue Neoplasms / Q000209:etiology / Q000601:surgery / Q000662:veterinary*
chemical_list: D011819:Rabies Vaccines